Acarix informs of exercise price for the warrants of series TO 3
Acarix AB ("Acarix" or the "Company"), a leader in rapid AI and acoustics-based cardiac diagnostics, announces that...
Acarix informs of exercise price for the warrants of series TO 3
Acarix AB ("Acarix" or the "Company"), a leader in rapid AI and acoustics-based cardiac diagnostics, announces that...
Acarix AB (publ) publishes Interim Report, April – June 2024
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 20...
Acarix AB (publ) publishes Interim Report, April – June 2024
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 20...
Announcement from the annual general meeting in Acarix AB
The annual general meeting 2024 (the "AGM") of Acarix AB ("Acarix" or the "Company") was held today on 14...
Kommuniké från årsstämma i Acarix AB
Årsstämman 2024 i Acarix AB ("Acarix" eller "Bolaget") hölls idag den 14 maj 2024 varvid aktieägarna fattade följan...
Acarix AB (publ) publishes Interim Report, January – March 2024
Setting the stage for a strong 2024 and beyond
One of the most notable achievements this quarter has been the successful implementation...
Proposal by the nomination committee prior to the 2024 annual general meeting of Acarix AB (publ)
The Nomination Committee of Acarix consists of Jan Poulsen (Chairman) representing Life Science Invest Fund 1 among others, Anton Rehns...
Acarix AB’s Annual Report 2023
Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2023 is available as a pdf ...
Acarix AB’s Årsredovisning 2023
Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, meddelar idag att årsredovisning för 2023 finns tillgänglig som pdf på b...
Acarix offentliggör utfall av utnyttjande av teckningsoptioner av serie 2024:U1 (TO2)
Styrelsen för Acarix AB (”Acarix” eller ”Bolaget”) offentliggör idag utfallet av utnyttjandeperioden för teckningsoptioner av serie 202...
Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)
The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period ...